Weight loss is 12.4% in trials (vs 15-22% for injectables), but self-pay pricing is significantly lower ($149-$349/month vs $1,000+/month for injectables)
The authors of Weighing the Impacts of GLP-1s: Quasi-Experimental Evidence from Provider Adoption acknowledge support from the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowships, and Jasmin Moshfegh acknowledges support from The Big Data Scientist Training Enhancement Program

Contact your healthcare provider immediately if you experience: Signs of dehydration, including decreased urination, dark urine, extreme thirst, dizziness, or lightheadedness Blood in stools or black, tarry stools Severe abdominal pain or cramping that doesn't resolve Fever above 101F (38.3C) accompanying diarrhea Unintentional weight loss beyond expected therapeutic effects Persistent nausea and vomiting preventing adequate fluid intake Symptoms of pancreatitis, including severe upper abdominal pain radiating to the back Signs of gallbladder disease, such as right upper quadrant pain, fever, or yellowing of skin/eyes Symptoms of kidney problems, including reduced urine output, swelling, or confusion These warning signs may indicate complications requiring urgent evaluation
The STEP trials and subsequent real-world data show semaglutide produces 1215% body weight reduction through appetite suppression and metabolic regulation mechanisms that glutathione doesnt influence